Advertisement

Clinical Rheumatology

, Volume 33, Issue 10, pp 1495–1500 | Cite as

Prevalence of cardiovascular risk factors in patients with psoriatic arthritis

  • Majed KhraishiEmail author
  • Rana Aslanov
  • Emmanouil Rampakakis
  • Clare Pollock
  • John S. Sampalis
Original Article

Abstract

Psoriatic arthritis (PsA) is a chronic T cell-mediated inflammatory spondyloarthropathy affecting 10–40 % of psoriasis (PSO) patients (0.3–1.0 % of the general population). Recent epidemiological studies have shown an increased prevalence of cardiovascular (CV) risk factors and/or morbidity among PSO or PsA patients as compared to control individuals. The aim of this study is to describe the CV profile of PsA patients in Newfoundland, Canada. The possible impact of duration of chronic inflammation on CV variables was also explored. PsA patients were selected from a registry of PSO and PsA patients in Newfoundland. PsA patients diagnosed as per the CASPAR criteria are entered in the registry at the time of diagnosis, questioned on their medical history, and are followed indefinitely. Based on the duration since PsA diagnosis patients were classified as having early (<2 years) or established (≥2 years) PsA. CV risk was assessed using both conventional (hypertension, hypercholesterolemia, diabetes, obesity) and non-conventional (markers of chronic inflammation) factors. A total of 196 PsA patients were included; 42.9 % had early PsA and 57.1 % had established PsA. The prevalence of hypercholesterolemia, obesity, hypertension, diabetes mellitus, anxiety/depression, and coronary heart disease was 61.6, 59.7, 32.7, 13.8, 13.8, and 8.7 %, respectively. The prevalence of comorbidities was generally comparable between cohorts with exception of anxiety/depression, which was considerably higher in patients with established PsA compared to early PsA and obesity which was more common among male patients with established PsA. However, upon adjusting for age and gender differences, no statistically significant between-group differences were observed. Overall, these results suggest that PsA, even at early stages, is associated with significant CV comorbidity. These conditions should be taken into consideration when assessing the PsA burden of illness in epidemiological and health outcomes studies. Furthermore, early detection and management of these conditions could improve the patients’ disability and quality of life.

Keywords

Cardiovascular Comorbidities Early PsA Established PsA Heart disease Psoriatic arthritis 

Notes

Conflict of interest

Majed Khraishi is partially funded by non-restricted grants from Abbott Canada, Amgen/Wyeth Canada, and Wyeth (later Pfizer) and supported by JSS Medical Research Inc. Rana Aslanov declared none. Emmanouil Rampakakis, Clare Pollock, and John S. Sampalis are employees of JSS Medical Research Inc.

References

  1. 1.
    National Psoriasis Foundation. Statistics. In. 2014.Google Scholar
  2. 2.
    Khraishi M, Chouela E, Bejar M, Landells I, Hewhook T, Rampakakis E, Sampalis JS, Abouchehade K (2012) High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg 16:122–127PubMedGoogle Scholar
  3. 3.
    Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaci D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol 69:729–735PubMedCrossRefGoogle Scholar
  4. 4.
    Prodanovich S, Kirsner RS, Kravetz JD, Ma F, Martinez L, Federman DG (2009) Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol 145:700–703PubMedCrossRefGoogle Scholar
  5. 5.
    Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735–1741PubMedCrossRefGoogle Scholar
  6. 6.
    Christophers E (2007) Comorbidities in psoriasis. Clin Dermatol 25:529–534PubMedCrossRefGoogle Scholar
  7. 7.
    Kim N, Thrash B, Menter A (2010) Comorbidities in psoriasis patients. Semin Cutan Med Surg 29:10–15PubMedCrossRefGoogle Scholar
  8. 8.
    Vena GA, Vestita M, Cassano N (2010) Psoriasis and cardiovascular disease. Dermatol Ther 23:144–151PubMedCrossRefGoogle Scholar
  9. 9.
    Wong K, Gladman DD, Husted J, Long JA, Farewell VT (1997) Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 40:1868–1872PubMedCrossRefGoogle Scholar
  10. 10.
    Han C, Robinson DW Jr, Hackett MV, Paramore LC, Fraeman KH, Bala MV (2006) Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 33:2167–2172PubMedGoogle Scholar
  11. 11.
    Khraishi M, MacDonald D, Rampakakis E, Vaillancourt J, Sampalis JS (2011) Prevalence of patient-reported comorbidities in early and established psoriatic arthritis cohorts. Clin Rheumatol 30:877–885PubMedCrossRefGoogle Scholar
  12. 12.
    Kondratiouk S, Udaltsova N, Klatsky AL (2008) Associations of psoriatic arthritis and cardiovascular conditions in a large population. Perm J 12:4–8PubMedPubMedCentralGoogle Scholar
  13. 13.
    Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT (2009) Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis 68:1131–1135PubMedCrossRefGoogle Scholar
  14. 14.
    Husted JA, Thavaneswaran A, Chandran V, Eder L, Rosen CF, Cook RJ, Gladman DD (2011) Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken ) 63:1729–1735CrossRefGoogle Scholar
  15. 15.
    Gonzalez-Juanatey C, Llorca J, Migo-Diaz E, Dierssen T, Martin J, Gonzalez-Gay MA (2007) High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 57:1074–1080PubMedCrossRefGoogle Scholar
  16. 16.
    Tam LS, Shang Q, Li EK, Tomlinson B, Chu TT, Li M, Leung YY, Kwok LW, Wong KC, Li TK, Yu T, Zhu TY, Kun EW, Yip GW, Yu CM (2008) Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum 59:1322–1331PubMedCrossRefGoogle Scholar
  17. 17.
    Peters MJ, Van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT (2004) Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 34:585–592PubMedCrossRefGoogle Scholar
  18. 18.
    Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673PubMedCrossRefGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2014

Authors and Affiliations

  • Majed Khraishi
    • 1
    • 2
    Email author
  • Rana Aslanov
    • 1
  • Emmanouil Rampakakis
    • 3
    • 4
  • Clare Pollock
    • 3
  • John S. Sampalis
    • 3
    • 4
  1. 1.Memorial University of NewfoundlandSt. John’sCanada
  2. 2.Nexus Clinical ResearchSt. John’sCanada
  3. 3.JSS Medical ResearchSt-LaurentCanada
  4. 4.McGill UniversityMontrealCanada

Personalised recommendations